USPTO serial 79185414
NEMAURA
Reviewed by CopyMark Law Group
Reg. 5293350Status 404
- Filing date
- Status date
- Registration date
- Sep 26, 2017
- Examiner
- ROSENBLATT, ANNA
- Law office
- FILE DESTROYED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEMAURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ali R. Latifi
Ali R. Latifi Tucker & Latifi, LLP160 East 84th StreetSuite 5ENew York, NY 10028Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical and veterinary preparations for treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Sanitary preparations for medical purposes; Diagnostic preparations and substances for medical or veterinary purposes; Medical diagnostic reagents; Antiserums for medical or veterinary diagnostic purposes; Vaccines for human beings and animals; Adjuvants for use with vaccines; Biological laboratory preparations for medical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Chemical preparations and reagents for medical, pharmaceutical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Viruses for the treatment of humans and animals for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Diagnostic preparations for medical purposes; In-vitro diagnostics for medical purposes; In-vivo diagnostics for medical purposes; Medical plasters; Transdermal patches for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal plasters for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal therapeutic drug delivery systems (TTS), namely, transdermal patches and plasters treated or impregnated with pharmaceutical active ingredients for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Medicated transdermal drug delivery patches featuring medication for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Vaccines; Drug delivery agents in the form of dissolvable films, coatings for tablets, capsules that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for injection in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Drug delivery agents in the form of liquid medications, tablets, powders, capsules, inhalants, nasal sprays, orally disintegrating tablets, and mouthwashes that facilitate the delivery of pharmaceutical preparations; Balms for medical purposes; Tonics for medical purposes, namely, for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Disinfectants, antiseptics ] | SECTION 71 - CANCELLED | — |
| 010 | [ Surgical apparatus and instruments for medical, dental or veterinary use; Suture materials; Inhalers for medical purposes; Filters for inhalers for medical purposes; Inhalers for medical use; Inhalers for therapeutic use; Electromagnetic drug delivery apparatus for medical use; Drug delivery apparatus and devices, namely, medical apparatus and units for dosage, measuring and monitoring; Microneedle arrays for delivering medications; Hypodermic syringes for injections for medical purposes; Electrical drug delivery apparatus for medical use; Needles for medical and surgical use; Hypodermic needles ] | SECTION 71 - CANCELLED | — |
| 042 | Medical research services; Conducting clinical trials for others; Medical research laboratory services; Medical research laboratory services for the analysis of samples taken from patients; Scientific analysis and research services, namely, DNA analysis services for scientific research purposes; Product development relating to pharmaceuticals, medicines, medicaments and veterinary products; Medical and health care testing services for research purposes, namely, clinical testing services, physician testing services for assisting pharmacists, pharmaceutical testing services, and medical laboratory and testing services; Pharmaceutical research and development services; Medical and scientific research information in the field of healthcare; Cosmetics research; Design and development of computer hardware and software and information storage retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nemaura Pharma Limited
- Other trademarks owned by Nemaura Pharma Limited
- Other trademarks owned by Nemaura Pharma Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named NEMAURA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 16, 2026 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jul 16, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jun 6, 2025 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 24, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 11, 2025 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 11, 2025 | INPC | INVALIDATION PROCESSED | — |
| Jan 23, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| May 23, 2024 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| May 23, 2024 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| May 20, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 26, 2023 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Sep 26, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 10, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 12, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 12, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 26, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 1, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 26, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 15, 2017 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 30, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 30, 2017 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 11, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 11, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 8, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 21, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 21, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 21, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 31, 2017 | EXPT | EXPARTE APPEAL TERMINATED | — |
| May 31, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 31, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 31, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 31, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 31, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 15, 2017 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 15, 2017 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| May 15, 2017 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| May 15, 2017 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Feb 2, 2017 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 14, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 14, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 14, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 21, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 21, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 21, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 22, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 22, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 22, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 21, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 5, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 1, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 31, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |